Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
DaShenLin Pharmaceutical Group Co., Ltd. on 6ix
Earlier from DaShenLin Pharmaceutical
- Announcement on Resolutions of the 2nd Meeting of the 5th Board of Directors
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on the Completion of Board of Directors Re-election and the Election of Company Chairman, Members of Special Committees under the Board of Directors, as well as the Appointment of Senior Management Member and Securities Affairs Representative
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Election of Board of Directors at Expiry of Term of Office
Later from DaShenLin Pharmaceutical
- Indicative Announcement on Change of the Meeting Date of the 2025 Annual General Meeting
- Announcement on Resolutions of the 2025 Annual General Meeting
- Indicative Announcement on Impending Expiration of 2020 Employee Stock Ownership Plan
- Indicative Announcement on Suspending Conversion of “Dashenlin Convertible Bonds" during the Implementation of Dividend Distribution for 2025
- Announcement on Adjustment of the Conversion Price of the “Dashenlin Convertible Bonds"
Follow DaShenLin Pharmaceutical into a list and get an email when it puts out news.
Follow DaShenLin Pharmaceutical